Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
You must be a Standard 1 Year member to access this content.
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Moderna, Inc. on the deal. Moderna, Inc. (Nasdaq:MRNA) announced its strategic collaboration with Generation Bio Co. (Nasdaq:GBIO) to combine Moderna’s biological and technical expertise with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Rapport Therapeutics, Inc. on the deal. Rapport Therapeutics, Inc. announced its launch with a $100 million Series A financing from Third Rock Ventures, ARCH...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised SonoThera, Inc. on the deal. SonoThera, Inc. announced its $60.75 million Series A financing round to support the continued development of SonoThera’s ultrasound-guided, nonviral,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Entrada Therapeutics, Inc. on the deal. Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to focus...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised FogPharma® on the deal. FogPharma® announced its $178 Million Series D financing. FogPharma is a biopharmaceutical company pioneering a new class of precision...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised SpringWorks Therapeutics on the deal. SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced its private placement transaction with a select group of institutional investors to issue...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Q32 Bio on the deal. Q32 Bio announced its collaboration and option agreement with Horizon Therapeutics Ireland DAC under which both companies will collaborate...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Palleon Pharmaceuticals on the deal. Palleon Pharmaceuticals announced its strategic collaboration agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize two bifunctional...
You must be a Standard 1 Year member to access this content.
